araag2/HINT huggingface dataset:
Clinical trial NCT02192190 (phase 2, status: terminated)
Conditions: osteoarthritis, knee
ICD codes: M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, M17.30
Drugs: ly2951742, celecoxib
SMILES: COC1=CC=C(C=C1)C(=O)CC(=O)C1=CC=C(C=C1)C(C)(C)C
Reason stopped: 
    interim assessment: lack of efficacy
  
Eligibility criteria:

        Inclusion Criteria:

          -  Have osteoarthritis (OA) of the knee joint based on American College of Rheumatology
             (ACR) criteria and confirmed with X-rays and ACR functional class of I to III

          -  Have been on stable dose of prescription Nonsteroidal Anti-Inflammatory Drugs
             (NSAIDS), celecoxib, tramadol, or acetaminophen of at least 2000 mg per day for at
             least 20 days in the past month

          -  Willing to stop all analgesics for OA pain during the study

          -  Experienced pain while walking in the target knee of 50-90 mm inclusive on 0-100
             Visual Analog Scale (VAS) with an increase in pain while walking of at least 10 mm
             following washout of current Osteoarthritis pain medications at screening

        Exclusion Criteria:

          -  Allergic to LY2951742, celecoxib, other NSAIDS, including aspirin, and similar drugs

          -  Arthritis of the knee from other causes

          -  Uncontrolled hypertension

          -  Have OA pain that requires treatment with potent opioids, systemic corticosteroids,
             intra-articular injections, duloxetine, or venlafaxine

          -  Moderate to severe renal impairment

          -  Pregnant or lactating
Clinical trial NCT02195700 (phase 2/phase 3, status: completed)
Conditions: tardive dyskinesia
ICD codes: K22.4, G24.01
Drugs: sd-809, placebo
SMILES: [2H]C([2H])([2H])OC1=CC2=C(C=C1OC([2H])([2H])[2H])[C@@H]1CC(=O)[C@@H](CC(C)C)CN1CC2, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  History of using a dopamine receptor antagonist for at least 3 months

          -  Clinical diagnosis of tardive dyskinesia and has had symptoms for at least 3 months
             prior to screening

          -  Subjects with underlying psychiatric diagnosis are stable and have no change in
             psychoactive medications

          -  Have a mental health provider and does not anticipate any changes to treatment regimen
             in the next 3 months

          -  History of being compliant with prescribed medications

          -  Able to swallow study drug whole

          -  Be in good general health and is expected to attend all study visits and complete
             study assessments

          -  Female subjects must not be pregnant and agree to an acceptable method of
             contraception

        Exclusion Criteria:

          -  Currently receiving medication for the treatment of tardive dyskinesia

          -  Have a neurological condition other than tardive dyskinesia that may interfere with
             assessing the severity of dyskinesias

          -  Have a serious untreated or undertreated psychiatric illness

          -  Have recent history or presence of violent behavior

          -  Have unstable or serious medical illness

          -  Have evidence of hepatic impairment

          -  Have evidence of renal impairment

          -  Have known allergy to any component of SD-809 or tetrabenazine

          -  Has participated in an investigational drug or device trial and received study drug
             within 30 days

          -  Have acknowledged use of illicit drugs

          -  Have a history of alcohol or substance abuse in the previous 12 months
Clinical trial NCT02195791 (phase 2, status: terminated)
Conditions: stroke
ICD codes: G46.4, G46.3, Z82.3
Drugs: pioglitazone, placebo
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    diffculty in participant enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          1. Acute ischemic stroke onset within 48 hours

          2. Age≧20 years

          3. Stroke severity with at least one point for limb weakness in National Institutes of
             Health Stroke Scale (NIHSS).

          4. The patients with no known history of diabetes with admission serum glucose ≧130
             mg/dl.

        Exclusion Criteria:

          1. The patients who have history of urinary bladder cancer or hematuira.

          2. The patients who have history of congestive heart failure or myocardial infarction.

          3. The patients who have known history of using pioglitazone before the onset of stroke.

          4. The patients who have mRS≧3 before stroke onset.
Clinical trial NCT02196688 (phase 2, status: completed)
Conditions: colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: fruquintinib, placebo
SMILES: CNC(=O)C1=C(C)OC2=CC(OC3=NC=NC4=CC(OC)=C(OC)C=C34)=CC=C12, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  ≥ 18 and ≤ 75 years of age , with ≥ 40 Kg

          -  Histological or cytological confirmed metastatic colorectal cancer

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1

          -  Failed 2 or more lines of chemotherapy

          -  Adequate hepatic, renal, heart, and hematologic functions

          -  At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)

          -  Signed and dated informed consent.

          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests, and other study procedure

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Any factors that influence the usage of oral administration

          -  Central nervous system (CNS) metastasis

          -  One of the following conditions: non-controlled hypertension, coronary artery disease,
             arrhythmia and heart failure

          -  Abuse of alcohol or drugs

          -  Less than 4 weeks from the last clinical trial - Previous treatment with VEGFR
             inhibition

          -  Disability of serious uncontrolled intercurrence infection

          -  Proteinuria ≥ 2+ (1.0g/24hr)

          -  Evidence or a history of bleeding tendency within two months of the enrollment,
             regardless of seriousness

          -  History of artery/venous thromboembolic events in 12 months, such as cerebral vascular
             accident (including transient ischemic attack) etc.

          -  History of acute myocardial infarction, acute coronary syndrome or coronary artery
             bypass graft (CABG) in 6 months

          -  Bone fracture or wounds that was not cured for a long time

          -  Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy
Clinical trial NCT02197065 (phase 2, status: completed)
Conditions: hip fracture, myocardial ischemia, inflammation
ICD codes: M84.359S, M84.459S, M84.359A, M84.459A, M84.359K, M84.359P, M84.459K, I25.6, P29.4, H01.9, H30.93, H05.00, H30.003, H30.013, H30.033, H30.103
Drugs: atorvastatin, placebo
SMILES: CC(C)C1=C(C(=O)NC2=CC=CC=C2)C(=C(N1CC[C@@H](O)C[C@@H](O)CC(O)=O)C1=CC=C(F)C=C1)C1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Hip fracture or elective hip or knee arthroplasty

          -  Age 65 years or older

          -  Life expectancy > 3 months

        Exclusion Criteria:

          -  Pathological hip fracture due to cancer

          -  Currently taking a statin, or took a statin within the last 30 days

          -  Previous statin intolerance

          -  Acute myocardial infarction or unstable angina

          -  History of myocardial infarction, acute coronary syndrome, angina, coronary/arterial
             re-vascularization

          -  Hip fracture patients with peripheral arterial disease

          -  Hip fracture patients with history of stroke or transient ischemic attack.

          -  Muscle disorder

          -  Serious liver disease or alanine aminotransferase > 3x upper limit of normal

          -  Serious renal disease (creatinine clearance <30cc/min)

          -  Treatment with HIV protease inhibitor or Hepatitis C protease inhibitor

          -  Treatment with erythromycin, clarithromycin, niacin or azole antifungal agent

          -  Pregnant, planning to become pregnant, or breastfeeding
Clinical trial NCT02197897 (phase 2, status: completed)
Conditions: bladder cancer
ICD codes: D30.3, C67.5, C67.9, C79.11, C67.0, C67.1, D41.4
Drugs: tamoxifen citrate
SMILES: COC1=CC(NCC2=C(C)C3=C(C=C2)N=C(N)N=C3N)=CC(OC)=C1OC
Eligibility criteria:

        Inclusion Criteria:

        Males and females age 21 or older. Histologic evidence of urothelial carcinoma of the
        bladder. Low/Intermediate-risk papillary urothelial carcinoma of the bladder, at initial
        occurrence or recurrent with >6 months interval free of disease.

        Patients with multifocal tumors must have resectable lesions. Patients may be
        treatment-naïve or have failed 1 previous regimen of intravesical therapy.

        At least one endoscopically measurable tumor 6 - 10mm in diameter. Adequate hepatic and
        renal function. Patient or authorized proxy needs to have signed the informed consent form.

        -

        Exclusion Criteria:

        Patients with sessile appearing tumors, which may be invasive or high-grade. Diagnosis of
        urothelial carcinoma involving the prostatic urethra or upper urinary tract.

        Plans for pelvic radiation while participating in the study. Concurrent use of warfarin,
        heparin, or chronic use of NSAIDs, including aspirin (other than cardioprotective doses of
        80mg daily) within 30 days prior to registration or during the trial.

        Concurrent use of selective serotonin reuptake inhibitors or aromatase inhibitors.

        Chronic or acute renal or hepatic disorder or any other condition, medical or psychological
        that, in the opinion of the investigator, could jeopardize the subject's safe
        participation.

        Any other investigational drug within 30 days prior to registration and during the study.

        Women Exclusion Pregnant or lactating women. Personal history of endometrial cancer or any
        abnormal uterine bleeding. Previous or concurrent treatment with SERM and/or hormonal
        replacement therapy within 3 months of the study.

        -
Clinical trial NCT02200354 (phase 2, status: terminated)
Conditions: advanced non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: pemetrexed with bevacizumab
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Reason stopped: 
    inclusion speed
  
Eligibility criteria:

        Inclusion Criteria:

          -  20 Years and older

          -  PS0-2

          -  Advanced non-squamous non-small cell lung cancer; AND

          -  Patients who have received more than 4 cycles of pemetrexed therapy before the study

        Exclusion Criteria:

          -  Interstitial pneumonia; AND

          -  Abnormal blood test
Clinical trial NCT02203331 (phase 2, status: completed)
Conditions: endometriosis
ICD codes: N80.8, N80.9, N80.0, N80.1, N80.5, N80.2, N80.3
Drugs: placebo, levonorgestrel, anastrozole, lupron / leuprolide acetate
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H], CC(C)(C#N)C1=CC(=CC(CN2C=NC=N2)=C1)C(C)(C)C#N, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Premenopausal women18 years and above at the time of screening.

          -  Women with endometriosis confirmed by laparoscopy or laparotomy within the last ten
             years but not less than 8 weeks before the screening visit In Japan, diagnosis based
             on imaging (transvaginal ultrasound or MRI) also qualifies for inclusion.

          -  Moderate to severe endometriosis-associated pelvic pain (EAPP) of ≥5 in the last 28
             days before screening visit 1 measured on the numeric rating scale (NRS; i.e. 4-week
             recall period).

          -  At randomization: Adherence to the study procedures during the screening period, at
             least 24 diary entries of ESD item 1 during the last 28 consecutive days before the
             randomization visit, and a sum of the available ESD item 1 ('worst pain' on the daily
             NRS) entries during this period of at least 98 (corresponding to an average score of ≥
             3.5).

          -  Willingness to use only ibuprofen as rescue pain medication for EAPP, if needed
             according to investigator's instruction.

          -  Use of a non-hormonal barrier method (i.e. spermicide-coated condoms) for
             contraception from screening visit until the end of the study. This is not required if
             adequate contraception is achieved by vasectomy of the partner

        Exclusion Criteria:

          -  Pregnancy or lactation (less than three months since delivery, abortion, or lactation
             before start of treatment)

          -  Any diseases or conditions that can compromise the function of the body systems and
             could result in altered absorption, excessive accumulation, impaired metabolism, or
             altered excretion of the study drug

          -  Any diseases or conditions that might interfere with the conduct of the study or the
             interpretation of the results.

          -  Any disease or condition that may worsen under hormonal treatment according to the
             assessment and opinion of the investigator.

          -  Undiagnosed abnormal genital bleeding

          -  Wish for pregnancy during the study

          -  Regular use of pain medication due to other underlying diseases

          -  Non-responsiveness of endometriosis associated pelvic pain (EAPP) to GnRH-a or surgery
             (partial response is not exclusionary).
Clinical trial NCT02205814 (phase 2, status: completed)
Conditions: knee osteoarthritis
ICD codes: M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, M17.30
Drugs: fasitibant- low dose, fasitibant- intermediate dose, fasitibant- high dose, placebo comparator
SMILES: [Na+].[Cl-]
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female patients aged 40 to 80 years with BMI < 30 kg/m²

          -  Patient with Kellgren-Lawrence Grade 2 to 3, symptomatic primary osteoarthritis at the
             index knee (ACR criteria), for which an IA treatment is indicated

          -  Pain of moderate to severe intensity, even if treated with chronic doses of non
             steroidal antinflammatory drugs

        Exclusion Criteria:

          -  History of hypersensitivity/allergy to drugs including paracetamol and to
             disinfectants

          -  Any pharmacological treatment of concomitant disease(s) started or changed during 4
             weeks prior to randomisation, or likely to be changed during the course of the study

          -  Use of systemic or topical corticosteroids > 10 mg prednisolone equivalent per day, or
             immunosuppressant drugs

          -  Current use of any pain or OA medication (e.g. NSAIDs, COX-2 inhibitors, analgesics,
             antidepressive agents), including topical treatments

          -  Viscosupplementation to the target knee administered < 4 months prior to randomisation
             and/or scheduled during the course of the study

          -  Evidence of clinically significant hepatic disease or of moderate or severe renal
             insufficiency

          -  Current use of any medications that are substrate of CYP3A4 and/or moderate or strong
             CYP3A4 inhibitors

          -  Patients with any clinically relevant or unstable disease, or malignant neoplasms
             that, in the opinion of the Investigator, may pose the patient at risk, or confound
             the efficacy and safety results of the study

          -  Patients with any clinically relevant abnormal safety laboratory test results, and/or
             abnormalities in vital signs, and/or ECG parameters

          -  Pregnant and breastfeeding women

          -  Any sign of significant immunodeficiency, systemic infection, knee infection or knee
             bursitis

          -  Patients with bleeding diathesis or on therapy with anticoagulants
Clinical trial NCT02206776 (phase 2, status: terminated)
Conditions: obsessive-compulsive disorder
ICD codes: F42.8, F42.9, F60.5
Drugs: intranasal ketamine, intranasal midazolam
SMILES: CNC1(CCCCC1=O)C1=CC=CC=C1Cl, CC1=NC=C2CN=C(C3=CC=CC=C3F)C3=C(C=CC(Cl)=C3)N12
Reason stopped: 
    poor tolerability and low enrollment rate
  
Eligibility criteria:

        Inclusion Criteria:

          -  Age 18-55

          -  Physically healthy and not currently pregnant

          -  Primary diagnosis of OCD

          -  Sufficient severity of symptoms

          -  For all patients on medications, medications dose must be stable for at least 6 weeks
             prior to enrollment. Must discuss with Dr. current medications and doses.

          -  Able to provide consent

        Exclusion Criteria:

          -  First degree relative with schizophrenia

          -  Psychiatric conditions that would make participation unsafe determined by study doctor

          -  Female patients who are either pregnant or nursing

          -  Planning to start EX/RP during the period of the study or those who have completed an
             adequate dose of EX/RP (defined as 8 or more sessions within 2 months) within 8 weeks
             prior to enrollment.

          -  Nasal obstruction or history of nasal surgery

          -  Currently on psychotropic medication or other medication likely to interact with the
             glutamate system

          -  Medical conditions that make participation unsafe

          -  Allergy or intolerance to ketamine or midazolam
Clinical trial NCT02210780 (phase 2, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: dupilumab, placebo
SMILES: CCO, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          1. Male or female adults ages 18 to 64 years with Chronic AD (according to the American
             Academy of Dermatology Consensus Criteria, [Eichenfeld 2004])that has been present for
             at least 3 years before the screening visit

          2. Participants with documented recent history (within 6 months before the screening
             visit) of inadequate response to a sufficient course of outpatient treatment with
             topical AD medication(s), or for whom topical AD therapies are otherwise inadvisable
             (e.g., because of side effects or safety risks).

          3. Eczema Area and Severity Index (EASI) score ≥16 at the screening visit and the
             baseline visit

          4. Investigator's Global Assessment (IGA) score ≥3 (on the 0-4 IGA scale) at the
             screening and baseline visits

          5. ≥10% body surface area (BSA) of AD involvement at the screening and baseline visits

        Key Exclusion Criteria:

          1. Prior treatment with dupilumab (REGN668/ SAR231893)

          2. Patients needing >10 mg of daily prednisone (including equivalent doses of other
             steroids) or high dose systemic corticosteroids (≥2 mg/kg) for 14 days or longer
             during the 16 week treatment period of the study

          3. History of Guillain-Barre syndrome

          4. History of severe allergic reaction to either vaccine or to vaccine components
             including alum, thimerosal, phenol

          5. Patients with a severe reaction to natural rubber latex products (some packaging
             components of the vaccines contain rubber latex and may cause a reaction in
             susceptible individuals)

          6. Treatment with biologics within 4 months of baseline visit

          7. Chronic or acute infection requiring treatment with antibiotics, antivirals,
             antiparasitics, antifungals within 4 weeks before screening visit or superficial skin
             infections within 1 week of screening visit

        The information listed above is not intended to contain all considerations relevant to a
        patient's potential participation in a clinical trial and not all inclusion/ exclusion
        criteria are listed.
Clinical trial NCT02211417 (phase 2, status: completed)
Conditions: atopic dermatitis
ICD codes: L20.89, L20.9
Drugs: ds107g, placebo
SMILES: CCCCC\C=C/C\C=C/C\C=C/CCCCCCC(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female subject aged 18 years and older.

          -  Moderate to severe atopic dermatitis.

        Exclusion Criteria:

          -  Clinically significant impairment of renal or hepatic function.

          -  History of hypersensitivity to any substance in DS107G or placebo capsules.

          -  Treatment with any experimental drug within 30 days prior to Day 0 visit (baseline).

          -  Excessive sun exposure, use of tanning booths or other ultraviolet (UV) light sources
             and/or is planning a trip to sunny climate.
Clinical trial NCT02212197 (phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: leuprolide acetate fluidcrystal® injection depot, leuprolide acetate
SMILES: CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O, CC(C)C[C@H](NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=CC=CC=C12)NC(=O)[C@H](CC1=CN=CN1)NC(=O)[C@@H]1CCC(=O)N1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@H]1C(=O)NNC(N)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Men ≥40 and ≤85 years of age

          -  Histological or cytological proven adenocarcinoma of the prostate requiring hormone
             therapy

          -  Life expectancy over 12 months

          -  World Health Organisation/ The Eastern Cooperative Oncology Group (WHO/ECOG)
             performance status of 0, 1 or 2

          -  Adequate and stable renal function

          -  Adequate and stable hepatic function

        Exclusion Criteria:

          -  Evidence of brain metastasis, spinal cord compression, or urinary tract obstruction

          -  Serum Testosterone levels below 150 ng/dL at Screening visit

          -  Medical or radiological prostate cancer treatments within 2 months prior to the
             Screening visit

          -  Surgical treatment of prostate cancer within 2 weeks prior to the Screening visit

          -  Prior orchiectomy, hypophysectomy, or adrenalectomy

          -  Prior use of LHRH agonists within 12 months prior to the Screening visit and during
             the study